^
Association details:
| Biomarker: | EGFR L861R |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report
Published date:
11/12/2021
Excerpt:
The patient was diagnosed with advanced lung cancer...The patient underwent genetic testing, and next-generation sequencing detected rare EGFR mutations L861R in the plasma (mutation abundance 8.1%). The patient was then administered afatinib at 30 mg quaque die combined with bevacizumab at 300 mg every 2 weeks....After 1 month of treatment, the patient achieved a quick response, and symptoms improved significantly.
DOI:
10.1097/MD.0000000000027614
